OS and RFS. (A) Predicted 5-year overall survival (OS) was 48% for the idarubicin group (IDR; n = 532; red line) and 48% for the daunorubicin group (DNR; n = 525; blue line; P = .54). (B) Predicted 5-year relapse-free survival (RFS) was 41% for the idarubicin group (IDR; n = 416; red line) and 41% for the daunorubicin group (DNR; n = 407; blue line; P = .97).